Inhibition of Human Platelet Aggregation and Calcium-Dependent, Phospholipase A2 Activity by Calcium Antagonists: Evidence for Intracellular Effects of Calcium Slow Channel Blockers

  • Richard C. Franson
  • Herbert Evans
  • Jayanti Thakkar
  • Nick Sperelakis
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 39)


Recent studies demonstrate that calcium antagonists, such as bepridil and verapamil, enter and accumulate in muscle cells, and suggest that these drugs may have intracellular effects in addition to their role as inhibitors of the slow inward Ca2+ current (1,2). Therefore, we have tested a group of calcium “slow channel” blockers for their ability to inhibit human platelet aggregation, which requires extracellular Ca2+, and the activity of human platelet phospholipase A2,an enzyme that is calcium-dependent and is associated with intracellular membranes (3,4). All the calcium antagonists tested, except nifedipine, inhibited ADP-induced aggregation of human platelets. The extent of inhibition by a given concentration of bepridil increased with the time of preincubation with drug. D-600 and diltiazem were the most potent inhibitors of aggregation. Human platelet phospholipase A2 activity was maximally active at pH 7.0 and had an absolute requirement for, and was extremely sensitive to, low concentrations of CaCl2. Activity was stimulated 220% by 10-7 M D-600, was inhibited to different degrees by bepridil, nitrendipine, and verapamil, and was essentially unaffected by nifedipine, mesudipine, and higher concentrations of D-600. Inhibition of phospholipase A2 activity by bepridil was relieved by increasing concentrations of CaCl9. Bepridil, verapamil, and propranolol displaced 45Ca from the membranes of autoclaved E. coli. The differential effects of these calcium antagonists on human platelet phospholipase A2 activity suggest that these drugs may produce secondary effects inside the cell.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vogel S, Crampton R, Sperelakis N: Blockade of myocardial slow channels by bepridil (CERM-1978). J. Pharmacol. Exp. Ther. (210): 378–385, 1979.PubMedGoogle Scholar
  2. 2.
    Pang D, Sperelakis N: Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscle. Eur. J. Pharm. (87): 199–207, 1983.CrossRefGoogle Scholar
  3. 3.
    Trugnan G, Bereziat G, Manier MC, Polonovski J: Phospholipase activities in subcellular fractions of human platelets. Biochim. Biophys. Acta (573): 61–72, 1979.PubMedCrossRefGoogle Scholar
  4. 4.
    Jesse R, Franson R: Modulation of purified phospholipase A« activity from human platelets by calcium and indomethacin. Biochim. Biophys. Acta (575): 467–470, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    Fleckenstein A: Specific pharmacology of calcium in the myocardium, cardiac pacemakers and vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol (17): 149–166, 1977.CrossRefGoogle Scholar
  6. 6.
    Ikeda Y, Kikuchi M, Toyama K, Watanabe K, Ando Y: Inhibition of human platelet functions by verapamil. Thrombos. Haemostas. (45): 158–161, 1981.Google Scholar
  7. 7.
    Born GVR, Cross MJ: The aggregation of blood platelets. J. Physiol. (168): 178–195, 1963.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Thakkar J, Sperelakis N, Pang D, Franson R: Characterization of phospholipase A9 activity in rat aorta smooth muscle cells. Biochim. Biophys. Acta (750): 134–140, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    Franson R, Weir D, Thakkar J: Solubilization and characterization of a neutral-active and calcium-dependent, phospholipase A9 from rabbit heart and isolated chick embryo myocytes. J. Mol. Cell Cardiol. (15): 189–196, 1983.PubMedCrossRefGoogle Scholar
  10. 10.
    Bligh EG, Dyer WJ: A rapid method for total lipid extraction. Can. J. Physiol. (37): 911–917, 1959.CrossRefGoogle Scholar
  11. 11.
    Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein- dye binding. Anal. Biochem. (72): 248–254, 1976.PubMedCrossRefGoogle Scholar
  12. 12.
    Zucker MB, Grant RA: Nonreversible loss of platelet aggregation by calcium deprivation. Blood (52): 505–514, 1978.PubMedGoogle Scholar
  13. 13.
    Mras S, Sperelakis N: Bepridil (CERM-1978) and verapamil depression of contractions of rabbit aortic rings. Blood Vessels (18): 196–205, 1981.PubMedGoogle Scholar
  14. 14.
    Franson R, Weir D: Isolation and characterization of a membrane- associated, calcium dependent phospholipase A2 from rabbit lung. Lung (160): 275–284, 1982.PubMedCrossRefGoogle Scholar
  15. 15.
    Franson R: Intracellular metabolism of ingested phospholipids. In Knight G (ed) Liposomes from physical structure to therapeutic applications. Elsevier North Holland, 1981, pp. 349–380.Google Scholar
  16. 16.
    Kunze N, Nahas N, Trenor J, Wurl M: Effects of local anesthetics in phospholipases. Biochim. Biophys. Acta (441): 93–102, 1976.PubMedCrossRefGoogle Scholar
  17. 17.
    Franson R, Eisen D, Jesse R, Lanni C: Inhibition of highly purified mammalian phospholipases A? by nonsteroidal antiinflammatory agents. Biochem. J. (186): 633–636, 1980.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Hauser G, Pappu AS: Effects of propranolol and other cationic amphiphilic drugs on phospholipid metabolism. In: Horrocks L, Ansell G, Bocellati G (ed) Phospholipids in the nervous system. Raven Press, New York, 1982, pp. 283–300.Google Scholar
  19. 19.
    Singh J, Babcock D, Lardy H: Induction of accelerated acrosome reaction in guinea pig sperm. Biol. Reprod. (22): 566–570, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Richard C. Franson
    • 1
  • Herbert Evans
    • 1
  • Jayanti Thakkar
    • 1
  • Nick Sperelakis
    • 2
  1. 1.Department of BiochemistryMedical College of VirginiaRichmondUSA
  2. 2.Department of PhysiologyUniversity of Cincinnati, College of MedicineCincinnatiUSA

Personalised recommendations